Briefly, most markers indicating sensitivity are linked to the underlying ability to promote PD-L1 expression pathway (JAK/STAT, IL7R) or the ability of the tumor create (KMT2C, TP53) or mask neoantigens (B2M, PTEN, CDKN2A, KEAP1) [73,74,75,76,77,78,79]. The gene discussed is CDKN2A; the disease is neoplasm.